Can pharmaceutical care decrease the oxidative stress in type 2 diabetes mellitus?

Angélica Marchesi Lira-Meriguete,Mayara Paes Santos,Vivian Cerqueira de Souza Viana,Nadmy Arrivabene Zavaris Gonçalves,Rodrigo Rezende Kitagawa,Lorena Carnielli-Queiroz,Daniela Amorim Melgaço Guimarães do Bem,Rita de Cássia Ribeiro Gonçalves
DOI: https://doi.org/10.1016/j.biopha.2024.116178
IF: 7.419
2024-01-25
Biomedicine & Pharmacotherapy
Abstract:Type 2 diabetes mellitus (T2D) is a chronic metabolic disorder characterized by an increase in oxidative stress, which is itself related to development of T2D's main chronic complications. Oxidative stress caused by elevated production of reactive species of oxygen and decrease of antioxidant defense system level, leads to activation of lipid peroxidation (LPO) and oxidative lipoprotein modification with increasing atherogenicity. Therefore, the aim of this study was to evaluate whether pharmacotherapeutic follow-up in patients with T2D, users and non-users of insulin, interferes with the levels of oxidative stress, measuring lipid peroxidation and protein oxidation, nitric oxide and superoxide dismutase levels. After the follow-up, there was a decrease in nitric oxide levels and an increase in superoxide dismutase concentration for the group with insulin therapy. Accordingly, these results show that the proposed pharmaceutical care program reduced the oxidative stress levels, mainly in patients in insulin therapy, as a consequence, can impact in the surging of the main chronic complications in T2D.
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?